

# Electrocardiographic and Echocardiographic Abnormalities in Chagas Disease

## Findings in Residents of Rural Bolivian Communities Hyperendemic for Chagas Disease

Antonio B. Fernandez\*, Maria Carmo P. Nunes<sup>†</sup>, Eva H. Clark<sup>‡</sup>, Aaron Samuels<sup>§</sup>, Silvio Menacho<sup>||</sup>, Jesus Gomez<sup>¶</sup>, Ricardo W. Bozo Gutierrez<sup>#</sup>, Thomas C. Crawford<sup>\*\*</sup>, Robert H. Gilman<sup>††</sup>, Caryn Bern<sup>‡‡</sup>

Hartford, CT, USA; Belo Horizonte, Brazil; Houston, TX, USA; Atlanta, GA, USA; Gutierrez, Camiri, and Santa Cruz, Bolivia; Ann Arbor, MI, USA; Baltimore, MD, USA; and San Francisco, CA, USA

### ABSTRACT

**Background:** Chagas disease is a neglected and preventable tropical disease that causes significant cardiac morbidity and mortality in Latin America.

**Objectives:** This study sought to describe cardiac findings among inhabitants of rural communities of the Bolivian Chaco.

**Methods:** The cardiac study drew participants from an epidemiologic study in 7 indigenous Guarani communities. All infected participants 10 years or older were asked to undergo a brief physical examination and 12-lead electrocardiogram (ECG). A subset had echocardiograms. ECG and echocardiograms were read by 1 or more cardiologists.

**Results:** Of 1,137 residents 10 years or older, 753 (66.2%) had *Trypanosoma cruzi* infection. Cardiac evaluations were performed for 398 infected participants 10 years or older. Fifty-five participants (13.8%) had 1 or more ECG abnormalities suggestive of Chagas cardiomyopathy. The most frequent abnormalities were bundle branch blocks in 42 (11.3%), followed by rhythm disturbances or ventricular ectopy in 13 (3.3%), and atrioventricular blocks (AVB) in 10 participants (2.6%). The prevalence of any abnormality rose from 1.1% among those 10 to 19 years old to 14.2%, 17.3%, and 26.4% among those 20 to 39, 40 to 59, and older than 60 years, respectively. First-degree AVB was seen most frequently in participants 60 years or older, but the 4 patients with third-degree AVB were all under 50 years old. Eighteen and 2 participants had a left ventricular ejection fraction of 40% to 54% and <40%, respectively. An increasing number of ECG abnormalities was associated with progressively larger left ventricular end-diastolic dimensions and lower left ventricular ejection fraction.

**Conclusions:** We found a high prevalence of ECG abnormalities and substantial evidence of Chagas cardiomyopathy. Programs to improve access to basic cardiac care (annual ECG, antiarrhythmics, pacemakers) could have an immediate impact on morbidity and mortality in these highly endemic communities.

Chagas disease is caused by the protozoan parasite *Trypanosoma cruzi*, most commonly transmitted to humans by hematophagous triatomine bugs in North, Central, and South Americas. An estimated 8 million people are currently infected with *T. cruzi*, and by far the highest infection prevalence is found in the ecological zone known as the Gran Chaco, shared among Bolivia, Argentina, and Paraguay [1]. In rural community surveys in the Bolivian Chaco, infection is found in >80% of adults [2,3].

The most significant clinical sequela of infection is Chagas cardiomyopathy. In the acute phase of the disease, most infected individuals are asymptomatic or

have nonspecific self-limiting febrile illness [4,5]. Anti-trypanosomal treatment has a high cure rate in the acute phase and is assumed to prevent chronic manifestations. However, acute infection is rarely diagnosed. Left untreated, 20% to 30% of infected individuals will progress to clinical heart disease, usually decades after the initial infection. Cohort studies in highly endemic areas demonstrate 2% to 3% annual incidence of cardiac disease [6], and a recent retrospective cohort analysis of Brazilian blood donors estimated a cardiomyopathy incidence rate of 1.85% per year [7].

The early signs of Chagas cardiomyopathy are typically conduction system abnormalities, most commonly right

Dr. Fernandez was supported by the National Institutes of Health (NIH)-funded grant "Interdisciplinary Framework in Global Health at Brown University" (no. 5R25TW008102). The other authors report no relationships that could be construed as a conflict of interests.

The funding sources had no role in the study design, collection, analysis and interpretation of the data, preparation of the manuscript, or the decision to submit for publication. This work was supported by NIH grant no. 5 P50 AI074285; NIH Fogarty Scholars Program (no. R24TW007988), NIH Training Grant in Infectious and Tropical Diseases (no. 5 T35 AI065385), NIH Global Research Training Grant (no. D43 TW006581).

From the \*Division of Cardiology, Hartford Hospital and University of Connecticut School of Medicine, Hartford, CT, USA; †School of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil; ‡Baylor College of Medicine, Houston, TX, USA; §Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA, USA; ||Centro de Salud, Eity, Gutierrez, Bolivia;

¶Hospital San Juan de Dios, Santa Cruz, Bolivia; #Hospital Municipal Camiri, Camiri, Bolivia;

\*\*Department of Cardiology, University of Michigan Health System, Ann Arbor, MI, USA; ††Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; and the ‡‡Department of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco, San Francisco, CA, USA.

Correspondence: A. B. Fernandez

(antoinefernandez@hotmail.com).

GLOBAL HEART  
© 2015 World Heart Federation (Geneva).  
Published by Elsevier Ltd.  
All rights reserved.  
VOL. 10, NO. 3, 2015  
ISSN 2211-8160/\$36.00.  
<http://dx.doi.org/10.1016/j.ghheart.2015.07.004>

bundle branch block (RBBB), often progressing to bifascicular blocks. Later manifestations include left ventricular systolic dysfunction, apical aneurysms, high-degree atrioventricular block, and sustained and nonsustained ventricular tachycardia [8]. Late cardiac manifestations are associated with high short-term mortality risk [9,10].

Vector-borne transmission remains the main infection route [5]. Observational data suggest that vector elimination may decrease progression to heart disease in endemic communities [11]. Vector control programs have decreased disease prevalence in many parts of Latin America [5]. However, the Bolivian Chaco continues to have high infestation rates and extremely high prevalence of *T. cruzi* infection [3]. Our objective in this study was to describe the electrocardiographic and echocardiographic findings among inhabitants of rural communities of the Bolivian Chaco.

## METHODS

The study took place in the Eity health sector (altitude 800 m), located in Gutierrez municipality, Cordillera province, Santa Cruz department. Data were collected from July 2011 to July 2012. The study site comprised 7 neighboring communities with a total population of approximately 2,200. The population is almost exclusively of the Native American Guaraní ethnicity, and the local economy is based on subsistence farming and animal husbandry. The study communities were chosen based on Ministry of Health data suggesting high likelihood of active *T. cruzi* transmission. Houses are predominantly constructed of mud and sticks or adobe, with packed dirt floors, and straw or corrugated metal roofs (Figure 1). Serosurvey methods and Chagas disease epidemiology were described in detail in an earlier publication [3].

## Ethics statement

The protocol approved by the institutional review boards of the Johns Hopkins University, Hospital Universitario Japones, Asociacion Benefica PRISMA, and the Centers for Disease Control and Prevention. Adult participants provided written informed consent. Written informed consent was obtained from the parent or guardian on behalf of children, and children older than 7 years provided written assent.

## Procedures

Demographic data and serum specimens were collected during the community survey during house-to-house visits [3]. All sera were tested by the indirect hemagglutination test (Chagas Polychaco, Lemos Labs, Export, PA, USA) and a whole parasite lysate enzyme-linked immunosorbent assay (Wiener Laboratories, Rosario, Argentina). Discordant specimens were tested by a third assay (Recombinante 3.0, Wiener Laboratories). Specimens with positive results by  $\geq 2$  assays were considered to have confirmed *T. cruzi* infection [12].

## Cardiac study

The cardiac study focused on seropositive participants 10 years and older; we were unable to include an age-comparable seronegative control group, because nearly all adults had *T. cruzi* infection. All eligible participants were asked to come to the health center for evaluation. Height, weight, blood pressure, and heart rate were recorded. A resting 12-lead electrocardiogram (ECG) and a 10-sec multilead rhythm strip were performed using a portable ECG machine (Welch Allyn CardioPerfect Workstation Software, Welch Allyn Inc., Skaneateles Falls, NY, USA). Two (in cases of discordancies, 3) cardiologists blinded to the participant's serologic status interpreted each ECG. Interpretation and coding were based on those developed by the Pan American Health Organization for use in epidemiological studies of Chagas heart disease [13]. The ECG findings assessed included rhythm, atrial and ventricular ectopy, ventricular and supraventricular arrhythmias, atrioventricular blocks (AVB), RBBB, left anterior fascicular block, left bundle branch block, left posterior fascicular block, nonspecific intraventricular conduction delay, ST-segment and T-wave abnormalities, low voltage, and right and left ventricular hypertrophy [13].

We categorized ECG abnormalities characteristic of Chagas cardiomyopathy into 3 categories: bundle branch blocks; AVB; and rhythm disturbances (including complex ventricular ectopy) [14]. An abnormal ECG suggestive of Chagas cardiomyopathy was defined as an ECG with complete RBBB, left anterior fascicular block, left posterior fascicular block, left bundle branch block, or bifascicular block; any degree of atrioventricular block; atrial fibrillation/flutter, junctional rhythm, sinus bradycardia with heart rate <50 beats/min, or complex ventricular ectopy. Incomplete RBBB was not included, as we and others have found this pattern can occur as a normal variant in physically active young adults [15]. Atrial ectopy, nonspecific ST-T wave changes, low voltage, and right or left ventricular hypertrophy were considered to be relatively nonspecific and were not included in our definition of an ECG suggestive of Chagas cardiomyopathy.

## Echocardiograms

An echocardiographer (A.F.) performed examinations during a 2-week field visit. Participants with abnormal ECG, plus as many of those with normal ECG as could be examined in available appointment times, were invited to undergo a 2-dimensional and Doppler echocardiogram at the Eity Health Center using a MicroMaxx Ultrasound machine (SonoSite, Inc., Bothell, WA, USA). Patients were examined in the left lateral recumbent position using standard parasternal and apical views. Two-dimensional measurements of the left ventricle (LV) were obtained following standard guidelines [16]. LV regional wall motion was based on the 17-segment model. Segments were classified as normal, hyperkinetic, hypokinesis, akinesis or dyskinesis, and aneurysmal. Mitral, tricuspid, aortic, and

pulmonary regurgitations were qualitatively evaluated. The presence of pericardial effusion was evaluated. Left ventricular end-diastolic diameter (LVEDD) is presented both as measured (considering 57 mm or above as dilation) and corrected for body surface area using this formula: for the corrected LVEDD, a result  $\geq 31$  mm was considered abnormal [16]. We considered LV ejection fractions of 40% to 54% as moderately decreased and  $<40\%$  as severely decreased [15,17]. The completion of echocardiograms was limited to the number of individuals able to reach the health center from the community during the echocardiographer's field visit. Some older adults who had not yet had an ECG were brought to the health center for echocardiogram by vehicle. Therefore, not all patients with abnormal ECG had echocardiographic data and vice versa. Only those with ECG data were included in the analysis of the echocardiographic data.

### Statistical analysis

Data were analyzed in SAS (version 9.0, SAS Institute Inc., Cary, NC, USA) and SPSS (version 18.0, SPSS Inc., Chicago, IL, USA). Continuous variables were compared using the Wilcoxon rank sum test or Kruskal-Wallis test. Categorical variables were compared using the Mantel-Haenszel chi-square (or 2-tailed Fisher exact test if expected cell values were  $<5$ ).

## RESULTS

### Characteristics of the study population

The overall study population comprised 1,580 participants, corresponding to 72% of the total estimated population of the villages. Of these, 1,137 were 10 years or older, 753 (66.2%) with *T. cruzi* infection and 384 (33.8%) without infection (Table 1). The infection prevalence rose steeply with increasing age, reflecting intense sustained vector-borne *T. cruzi* transmission over past decades [3]. Overall, 398 infected participants (53% of those in the eligible age range) reported to the health center for an ECG. Women were significantly more likely than men to join the cardiac substudy (59% vs. 44%;  $p < 0.001$ ), and participation was higher among older age groups (49% of 10- to 19-year-olds, 46% of 20- to 39-year-olds, 63% of 40- to 59-year-olds, and 57% of those older than 60 years).

### ECG data

The mean QRS duration was  $98.2 \pm 20.5$  ms and mean PR interval was  $150.3 \pm 26.0$  ms. The mean PR interval increased with increasing age (Figure 2). A total of 55 participants (3.5%) had ECG findings suggestive of Chagas cardiomyopathy (Table 2). Abnormalities fell into 3 categories: rhythm disturbances or ventricular ectopy; bundle branch blocks; and AVB. The most common abnormalities were bundle branch blocks, found in 42 participants (11.3%), followed by rhythm disturbances or ventricular ectopy in 13 (3.3%) and AVB in 10 (2.6%). Ten



**FIGURE 1.** A typical house in 1 of the study villages in Cordillera Province, Santa Cruz department, Bolivia.

of the 55 participants with abnormal ECG had findings in  $>1$  category (Table 3). The group with multiple abnormalities on ECG included 4 patients in need of pacemakers (patients 1, 2, 4, and 5).

The prevalence of abnormalities rose with increasing age, from 1.1% among those 10 to 19 years old to 14.2%, 17.3%, and 26.4% among those 20 to 39, 40 to 59, and older than 60 years, respectively (Figure 3). Bundle branch blocks composed most of the abnormalities seen in younger individuals. First-degree AVB was seen most frequently in participants 60 years or older, but the 4 patients with third-degree AVB were 30, 39, 46, and 47 years old.

### Echocardiographic data

Echocardiography data were available from 97 *T. cruzi*-infected participants. The median LVEDD was 44 mm (interquartile range [IQR]: 40, 49), whereas the median LV ejection fraction was 60% (IQR: 55, 65) (Table 4). Only 2 participants had LVEDD  $\geq 57$  mm; 13 had LVEDD corrected for body surface area above the published cutoff of 31 mm. Eighteen and 2 participants had LVEF 40% to 54% and  $<40\%$ , respectively. An increasing number of abnormalities on ECG was associated with progressively higher LVEDD and lower LV ejection fraction ( $p = 0.004$  and  $p = 0.02$  by Kruskal-Wallis test). Four individuals were found to have valvular heart disease, 1 with a combination of aortic and mitral valve disease, probably due to rheumatic heart disease, 1 with moderate mitral regurgitation, and 2 with aortic stenosis.

**TABLE 1.** Characteristics of the serosurvey population 10 years or older and cardiac substudy participants, Cordillera Province, Santa Cruz department, Bolivia

	Serosurvey Participants $\geq 10$ Years* <sup>†</sup>		ECG*	Echocardiograms <sup>‡</sup>
	Uninfected (n = 384)	<i>T. cruzi</i> –Infected (n = 753)	<i>T. cruzi</i> –Infected (n = 398)	<i>T. cruzi</i> –Infected (n = 97)
Male <sup>§</sup>	188 (49.0)	292 (38.8)	128 (32.2)	37 (38.1)
Female <sup>‡</sup>	196 (51.0)	461 (61.2)	270 (67.8)	60 (61.9)
Age group <sup>§</sup>				
10–19	346 (90.1)	187 (24.8)	92 (23.1)	4 (4.1)
20–39	33 (8.6)	264 (35.1)	120 (30.2)	24 (24.7)
40–59	5 (1.3)	210 (27.9)	133 (33.4)	42 (43.3)
$\geq 60$	0 (0)	92 (12.2)	53 (13.3)	27 (27.8)
Age, yrs <sup>  </sup>	13 (11, 15)	34 (20, 49)	38 (22, 51)	50 (38, 61)
BMI, kg/m <sup>2</sup>	—	—	24.4 (21.9, 28.2)	26.2 (23.0, 30.0)
Respiratory rate, per min	—	—	20 (16, 20)	20 (16, 20)
Heart rate, per min	—	—	67 (61, 73)	66 (58, 71)
Systolic blood pressure, mm Hg	—	—	110 (100, 120)	120 (110, 130)
Diastolic blood pressure, mm Hg	—	—	80 (70, 84)	80 (70, 90)

Values are n (column %) or median (interquartile range). Comparisons by chi-square for sex and by Wilcoxon rank sum for continuous variables. BMI, body mass index; ECG, electrocardiogram; *T. cruzi*, *Trypanosoma cruzi*.

\*Participants with ECG data were more likely to be female ( $p < 0.0001$ ) and were older ( $p < 0.05$ ) than other seropositive survey participants.

<sup>†</sup>Echocardiogram patients were older ( $p < 0.0001$ ), had higher BMI ( $p < 0.01$ ), lower heart rate ( $p < 0.01$ ), higher systolic ( $p < 0.01$ ) and diastolic BP ( $p < 0.05$ ) than seropositive survey participants did. They were also older ( $p < 0.0001$ ), had higher BMI ( $p < 0.01$ ), lower heart rate ( $p < 0.01$ ), higher systolic ( $p < 0.01$ ) and diastolic BP ( $p < 0.05$ ) than seropositive ECG recipients did; there was no difference between ECG and echocardiogram recipients by sex.


<sup>‡</sup>Female participants were more likely than male participants to be seropositive ( $p < 0.01$ ), but this difference was no longer significant ( $p = 0.73$ ) when controlled for age.

<sup>§</sup>Seropositive participants were significantly more likely to fall into older age categories than seronegative participants were ( $p < 0.05$ ).

<sup>||</sup>Seropositive participants were significantly older than seronegative participants were ( $p < 0.0001$ ).

## DISCUSSION

Chagas disease remains a major cause of morbidity and mortality in Latin America [18]. Despite progress in vector



**FIGURE 2.** Mean PR interval in milliseconds among 398 *Trypanosoma cruzi*-infected participants by age group. Error bars represent standard deviations.

control [19], communities with intense transmission remain, especially in the Gran Chaco [1–3]. Our study took place in one such area, where the majority of houses were still infested at the time of our survey and the force of infection was estimated at 4% per year [3]. We found ECG abnormalities suggestive of Chagas cardiomyopathy in nearly 15% of community residents ages 20 to 39 years, and more than 25% of those 60 or older, figures consistent with the estimate that 20% to 30% of infected individuals eventually develop heart disease [5]. Signs of dilated cardiomyopathy by echocardiogram were most frequent in the group of individuals with multiple abnormalities on ECG, a group that included 4 patients who needed pace-makers [20].

In our population, RBBB, alone or in combination with left anterior fascicular block, were the most frequent abnormalities consistent with Chagas cardiomyopathy. These findings are consistent with results of other community-based studies conducted in other parts of Bolivia and in Brazil [21–23]. In our data, the prevalence of ECG abnormalities rose steadily with age. A Brazilian study from the 1980s found the highest rate of ECG abnormalities in participants 25 to 44 years old and interpreted this finding as suggestive of excess mortality due to Chagas cardiomyopathy among older residents [21].

**TABLE 2.** ECG findings among 398 *T. cruzi*-infected study participants 10 years or older

PR interval in ms	150.3 ± 26.0
QRS interval in ms	98.2 ± 20.5
<b>Rhythm</b>	
Sinus bradycardia <50 beats/min	5 (1.3)
Junctional rhythm	4 (1.0)
Atrial fibrillation or flutter	2 (0.5)
Normal sinus rhythm	387 (97.2)
<b>Ectopy</b>	
Complex ventricular premature contractions*	2 (0.5)
Simple ventricular premature contractions	2 (0.5)
Atrial ectopic beats	4 (1.0)
<b>Bundle branch blocks</b>	
Isolated RBBB	11 (2.8)
Isolated LAFB	17 (4.3)
RBBB and LAFB	13 (3.3)
RBBB and LPFB	1 (0.3)
Incomplete RBBB	3 (0.75)
No block	353 (88.7)
<b>Atrioventricular blocks</b>	
First-degree AVB	7 (1.8)
Third-degree AVB	4 (1.0)
None	387 (97.2)
Any ECG abnormality suggestive of Chagas cardiomyopathy <sup>†,‡</sup>	55 (13.8)

Values are mean ± SD or n (%). ECG interpretation and coding followed methods in Lazzari et al. [13].  
 AVB, atrioventricular block; ECG, electrocardiogram; LAFB, left anterior fascicular block; LPFB, left posterior fascicular block; PVC, premature ventricular contraction; RBBB, right bundle branch block.  
 \*One multiform PVC, 1 ventricular bigeminy.  
 †Includes RBBB, LAFB, LPFB, bifascicular blocks, AVB, and these abnormal rhythms: junctional; atrial fibrillation/flutter; sinus bradycardia with heart rate <50 beats/min; multiform PVC; ventricular bigeminy. The following were not considered ECG abnormalities suggestive of Chagas cardiomyopathy: atrial ectopy; simple PVC; incomplete RBBB [14].  
 ‡Nine participants had abnormalities in 2 categories and 1 had abnormalities in 3 categories (see Table 3).

However, more recent studies show steadily increasing prevalence of abnormalities with age, perhaps due to better survival of affected individuals in recent decades [22–24]. Whereas we found the highest rates of bundle branch blocks and first-degree AVB in the oldest age group, third-degree AVB were found only among participants younger than 50 years, possibly reflecting premature mortality among those who had high-grade AVB for longer periods of time.

Direct comparisons of the prevalence of ECG abnormalities are impeded by the fact that each study used different criteria [21,22], and some studies fail to specify

the precise definitions used and the age groups surveyed [23]. We attempted to use rigorous criteria for defining ECG abnormalities. For the sake of higher specificity, we excluded incomplete RBBB, intraventricular conduction delays, low QRS voltage, and nonspecific ST-T wave changes from our definition of abnormal ECG, and we defined sinus bradycardia as heart rate <50 beats/min. We may have therefore excluded some individuals with changes due to *T. cruzi* infection. However, in recent publications from Brazil, low QRS voltage and ST-T wave changes were equally frequent among *T. cruzi*-infected and uninfected adults [24,25]. Especially in the absence of a seronegative comparator group, we considered specificity more important than sensitivity.

The direct linear relationship between PR prolongation and age in our study is intriguing. One of the Brazilian community studies demonstrated significantly longer mean PR interval among *T. cruzi*-infected study participants compared with that of uninfected participants, but apparently without age adjustment [23]. Among *T. cruzi*-infected blood donors, PR interval prolongation was significantly associated with LV dysfunction [25]. In another endemic area of Brazil, PR prolongation among Chagas disease patients was associated with a higher mortality risk [26]. Without an age-matched seronegative control group, we cannot unequivocally attribute this finding to Chagas cardiomyopathy, but further investigation may confirm PR interval as a useful prognostic parameter.


As expected in a community-based study, most of the abnormalities we found were relatively mild and the vast majority of our participants reported no cardiac symptoms. Because the evolution of Chagas cardiomyopathy occurs over multiple decades, a snapshot survey of the prevalence of cardiac abnormalities, especially in a young population, will reveal relatively few severe cases [8,21]. We found few participants with high-grade conduction system disease or dilated cardiomyopathy, and these abnormalities tended to occur in the same individuals. Those with multiple abnormalities on ECG were also those mostly likely to have a dilated LV and/or depressed LV ejection fraction, a finding consistent with the natural history of Chagas cardiomyopathy and with earlier studies comparing ECG and echocardiogram results [27].

It is important to note that our findings may underestimate the prevalence of severe disease, because severely ill community residents may have been unable to report to the health center for evaluation. Indeed, 2 seropositive patients with advanced cardiomyopathy—a 69-year-old woman with an apical aneurysm, ejection fraction of 30%, and severe right and left systolic dysfunction and a 72-year-old man with a LV aneurysm with thrombus, ejection fraction of 25%, and severe LV dysfunction—were excluded from the analysis because they lacked ECG. These patients were brought to the

**TABLE 3.** *T. cruzi*–infected participants with ECG abnormalities in ≥1 category (AVB, BBB, rhythm, ventricular ectopy)

Patient	Age, yrs	Sex	Bundle Branch Blocks	AVB	Arrhythmias	LV Ejection Fraction
1	30	Female	RBBB	Third-degree AVB	Junctional rhythm (43 beats/min)	40% to 45%
2	39	Female	None	Third-degree AVB	Junctional rhythm (40 beats/min)	35%
3	45	Male	LAFB	First-degree AVB	None	45% to 50%
4	46	Female	None	Third-degree AVB	Junctional rhythm (47 beats/min)	Not done
5	47	Female	None	Third-degree AVB	Junctional rhythm (45 beats/min)	Not done
6	48	Female	RBBB plus LAFB	None	Ventricular bigeminy	Not done
7	58	Male	LAFB	None	Sinus bradycardia (49 beats/min)	65%
8	63	Female	RBBB plus LAFB	None	Atrial fibrillation/flutter	40%
9	65	Male	RBBB plus LAFB	First-degree AVB	None	Not done
10	74	Female	LAFB	First-degree AVB	None	50%

BBB, bundle branch block; LV, left ventricular; other abbreviations as in Table 2.



**FIGURE 3.** Age-specific prevalence of electrocardiogram abnormalities among 398 *Trypanosoma cruzi*–infected participants: (A) right bundle branch block (RBBB), left anterior and posterior fascicular blocks (LAFB, LFPB); (B) atrioventricular blocks (AVB); (C) abnormal rhythms; and (D) 1 or more abnormalities suggestive of Chagas cardiomyopathy (see text and Table 2). Fib, fibrillation.

**TABLE 4.** Echocardiogram findings among 97 *T. cruzi*-infected study participants 10 years or older

Echocardiogram Findings	All tested (n = 97)	ECG Findings		
		Normal (n = 66)	Single Abnormality (n = 25)	Multiple Abnormalities (n = 6)
LVEDD, mm	44 (40, 49)	43 (40, 45)*	47 (41, 51)*	54 (49, 56)*
≥57 mm	2 (2.1)	0 (0)	1 (4.0)	1 (16.7)
LVEDD/BSA, mm <sup>†</sup>	27 (25,30)	26 (24,29)	27 (25, 30)	31 (29, 34)
≥31 mm	13 (13.4)	7 (10.6)	3 (12.0)	3 (50.0)
LVEF, %	60 (55, 65)	60 (55, 65) <sup>‡</sup>	60 (55, 60) <sup>‡</sup>	45 (40, 50) <sup>‡</sup>
40% to 54%	18 (18.6)	9 (13.6)	5 (20.0)	4 (66.7)
<40%	2 (2.1)	0 (0)	1 (4.0)	1 (16.7)

Values are median (interquartile range) or n (%).

BSA, body surface area; ECG, electrocardiogram; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction.

\*Data missing for 2 participants with normal ECG. Increasing number of ECG abnormalities associated with decreasing LVEDD,  $p = 0.004$  by Kruskal-Wallis test.

<sup>†</sup>LVEDD/BSA calculated as follows:  $BSA \text{ (in m}^2\text{)} = 0.007184 \times \text{height (cm)}^{0.725} \times \text{weight (kg)}^{0.425}$ . Cutoff of 31 mm based on Lang et al. [16].

<sup>‡</sup>Data missing for 1 participant with normal ECG. Increasing number of ECG abnormalities associated with decreasing LVEF,  $p = 0.02$  by Kruskal-Wallis test.

health center by vehicle during the echocardiographer's visit, but they likely were unable to walk to the health center later for their ECG. Other limitations of our study are related to the absence of an appropriate seronegative control group. We assume that our ECG and echo findings were related to *T. cruzi* infection, but despite using the most specific definitions we could design, some of the findings may still have been related to other cardiovascular diseases.

## CONCLUSIONS

We found a high prevalence of ECG abnormalities and substantial evidence of Chagas cardiomyopathy in these highly endemic communities, with rates and patterns similar to those seen in community studies from other areas in the Southern Cone. We found ≥4 participants with sustained or intermittent complete heart block who could benefit from pacemaker implantation. However, access to pacemakers and other advanced cardiac interventions is severely limited in rural southern Bolivia. Programs to improve access to basic cardiac care (annual ECG, antiarrhythmics, pacemakers) could have an immediate impact on morbidity and mortality in these hyperendemic villages.

## ACKNOWLEDGMENTS

The authors are grateful to the population of the Eity Health Sector for their time and cooperation in the study and to Gerson Galdos for facilitation and support. For their dedicated work in the field, they thank Evelin Coromechi, Bernardo Salvador, Anahi Porcel, Javier Loayza, and Keith Fischer.

## REFERENCES

- Gürtler RE. Sustainability of vector control strategies in the Gran Chaco Region: current challenges and possible approaches. *Mem Inst Oswaldo Cruz* 2009;104(Suppl 1):52–9.
- Chippaux JP, Postigo JR, Santalla JA, Schneider D, Brutus L. Epidemiological evaluation of Chagas disease in a rural area of southern Bolivia. *Trans R Soc Trop Med Hyg* 2008;102:578–84.
- Samuels AM, Clark EH, Galdos-Cardenas G, et al., for the Working Group on Chagas Disease in Bolivia and Peru. Epidemiology of and impact of insecticide spraying on Chagas disease in communities in the Bolivian Chaco. *PLoS Negl Trop Dis* 2013;7:e2358.
- Dias JC. Natural history of Chagas' disease [in Portuguese]. *Arq Bras Cardiol* 1995;65:359–66.
- Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. *Lancet* 2010;375:1388–402.
- Fernandes AJ, Chiari E, Casanova C, Dias JC, Romanha AJ. The threat of reintroduction of natural transmission of Chagas' disease in Bambuí, Minas Gerais State, Brazil, due to *Panstrongylus megistus*. *Mem Inst Oswaldo Cruz* 1992;87:285–9.
- Sabino EC, Ribeiro AL, Salemi VM, et al., for the NHLBI REDS-II International Component. Ten-year incidence of Chagas cardiomyopathy among asymptomatic *Trypanosoma cruzi*-seropositive former blood donors. *Circulation* 2013;127:1105–15.
- Rassi A Jr, Rassi A, Little WC. Chagas' heart disease. *Clin Cardiol* 2000; 23:883–9.
- Mady C, Cardoso RH, Barretto AC, da Luz PL, Bellotti G, Pileggi F. Survival and predictors of survival in patients with congestive heart failure due to Chagas' cardiomyopathy. *Circulation* 1994;90: 3098–102.
- Rassi A Jr, Rassi A, Little WC, et al. Development and validation of a risk score for predicting death in Chagas' heart disease. *N Engl J Med* 2006;355:799–808.
- Acquatella H, Cataliotti F, Gomez-Mancebo JR, Davalos V, Villalobos L. Long-term control of Chagas disease in Venezuela: effects on serologic findings, electrocardiographic abnormalities, and clinical outcome. *Circulation* 1987;76:556–62.
- WHO. Expert Committee Control of Chagas Disease. Brasilia, Brazil: World Health Organization; 2002. p. 1–109.
- Lázzari JO, Pereira M, Antunes CM, et al. Diagnostic electrocardiography in epidemiological studies of Chagas' disease: multicenter evaluation of a standardized method. *Rev Panam Salud Publica* 1998; 4:317–30.

14. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. *JAMA* 2007;298:2171–81.
15. Le VV, Wheeler MT, Mandic S, et al. Addition of the electrocardiogram to the preparticipation examination of college athletes. *Clin J Sport Med* 2010;20:98–105.
16. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr* 2005;18:1440–63.
17. Okamoto EE, Sherbuk JE, Clark EH, et al., for the Chagas Disease Working Group in Bolivia and Peru. Biomarkers in *Trypanosoma cruzi*-infected and uninfected individuals with varying severity of cardiomyopathy in Santa Cruz, Bolivia. *PLoS Negl Trop Dis* 2014;8:e3227.
18. Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. *Heart* 2009;95:524–34.
19. Dias JC. Southern Cone Initiative for the elimination of domestic populations of *Triatoma infestans* and the interruption of transfusional Chagas disease: historical aspects, present situation, and perspectives. *Mem Inst Oswaldo Cruz* 2007;102(Suppl 1): 11–8.
20. Clark EH, Sherbuk J, Okamoto E, et al., for the Working Group on Chagas Disease in Bolivia and Peru. Hyperendemic Chagas disease and the unmet need for pacemakers in the Bolivian Chaco. *PLoS Negl Trop Dis* 2014;8:e2801.
21. Maguire JH, Mott KE, Lehman JS, et al. Relationship of electrocardiographic abnormalities and seropositivity to *Trypanosoma cruzi* within a rural community in northeast Brazil. *Am Heart J* 1983;105: 287–94.
22. Pless M, Juranek D, Kozarsky P, Steurer F, Tapia G, Bermudez H. The epidemiology of Chagas' disease in a hyperendemic area of Cochabamba, Bolivia: a clinical study including electrocardiography, seroreactivity to *Trypanosoma cruzi*, xenodiagnosis, and domiciliary triatomine distribution. *Am J Trop Med Hyg* 1992;47: 539–46.
23. Williams-Blangero S, Magalhaes T, Rainwater E, Blangero J, Corrêa-Oliveira R, Vandenberg JL. Electrocardiographic characteristics in a population with high rates of seropositivity for *Trypanosoma cruzi* infection. *Am J Trop Med Hyg* 2007;77:495–9.
24. Ribeiro AL, Marcolino MS, Prineas RJ, Lima-Costa MF. Electrocardiographic abnormalities in elderly Chagas disease patients: 10-year follow-up of the Bambui Cohort Study of Aging. *J Am Heart Assoc* 2014;3:e000632.
25. Ribeiro AL, Sabino EC, Marcolino MS, et al., for the NHLBI REDS-II International Component. Electrocardiographic abnormalities in *Trypanosoma cruzi* seropositive and seronegative former blood donors. *PLoS Negl Trop Dis* 2013;7:e2078.
26. Goncalves JG, Dias Silva VJ, Calzada Borges MC, Prata A, Correia D. Mortality indicators among chronic Chagas patients living in an endemic area. *Int J Cardiol* 2010;143:235–42.
27. Nascimento BR, Araujo CG, Rocha MO, et al. The prognostic significance of electrocardiographic changes in Chagas disease. *J Electrocardiol* 2012;45:43–8.